Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions Against Th2 Cytokine-Mediated Signaling
August 2023
in “
Molecules
”
Studysummary This study found that a quinazoline derivative, SH-340, increased skin barrier-associated factors and inhibited TSLP expression and STAT6 phosphorylation in human primary keratinocytes, suggesting potential benefits for alleviating inflammation and improving skin barrier function in atopic dermatitis.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study explores the potential of a novel quinazoline derivative, SH-340, as a treatment for atopic dermatitis (AD) by enhancing skin barrier functions and counteracting Th2 cytokine-mediated signaling. SH-340 was tested on human primary keratinocytes, showing significant cytotoxicity at concentrations from 0.5 to 25 μM, inhibiting proliferation, and inducing differentiation with increased expression of markers like KRT1, KRT10, and FLG. It also inhibited IL-4/IL-13-induced STAT6 phosphorylation by 45% and suppressed TSLP production, suggesting its ability to alleviate AD-related pruritus. These findings indicate that SH-340 could be a promising candidate for developing more effective AD treatments, although further research is needed to fully understand its mechanisms and ensure its safety.
